• BIOCORP and Merck KGaA, Darmstadt, Germany, partner for the development and worldwide distribution of a specific version of Mallya for drug delivery devices
• BIOCORP and Merck KGaA, Darmstadt, Germany, extend their collaboration after an already ongoing program
• BIOCORP will receive payments for development plus revenue from post-launch sales, after the validation of several key milestones
Issoire, October 10, 2022, 7:30 a.m. CEST – BIOCORP (FR0012788065 – ALCOR / PEA‐PME eligible), a French company specializing in the development and manufacture of medical devices and injectable drug delivery systems, and Merck KGaA, Darmstadt, Germany, a leading science and technology company, have entered into an agreement for the development and supply of a specific version of the Mallya device as an accessory for one of the drug delivery devices of Merck KGaA, Darmstadt, Germany.
Manufactured in Clermont-Ferrand (France), Mallya is a smart device for injection pens, which collects the dose and time of each injection and transfers the information in real time to a smartphone application. Mallya was the first in its class to receive CE (medical device) marking and commercial versions for insulin pens are already available and distributed in Europe and other countries.